Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- AZT.OL
- Price
- 22.00
- Stock movement up
- +1.00 (4.35%)
- Company name
- Arcticzymes Technologies ASA
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 1.23B
- Ent value
- 1.07B
- Price/Sales
- 11.89
- Price/Book
- 3.71
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- 160.08
- Forward P/E
- 59.67
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 29.03%
- 3 year return (CAGR)
- -16.47%
- 5 year return (CAGR)
- -20.34%
- 10 year return (CAGR)
- 8.52%
Last updated: 2026-02-27
DIVIDENDS
AZT.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 160.08 |
| Price to OCF | 65.14 |
| Price to FCF | 193.91 |
| Price to EBITDA | 171.21 |
| EV to EBITDA | 148.89 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 11.89 |
| Price to Book | 3.71 |
| EV to Sales | 10.34 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 51.07M |
| EPS (TTM) | 0.15 |
| FCF per share (TTM) | 0.12 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 103.07M |
| Gross profit (TTM) | 98.36M |
| Operating income (TTM) | -2.62M |
| Net income (TTM) | 7.66M |
| EPS (TTM) | 0.15 |
| EPS (1y forward) | 0.40 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 95.42% |
| Operating margin (TTM) | -2.54% |
| Profit margin (TTM) | 7.43% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 182.30M |
| Net receivables | 13.34M |
| Total current assets | 296.13M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 18.35M |
| Total assets | 352.97M |
| Accounts payable | 4.07M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 18.11M |
| Total liabilities | 22.50M |
| Shareholder's equity | 330.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 18.82M |
| Capital expenditures (TTM) | 12.50M |
| Free cash flow (TTM) | 6.32M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 2.32% |
| Return on Assets | 2.17% |
| Return on Invested Capital | 2.32% |
| Cash Return on Invested Capital | 1.91% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 22.70 |
| Daily high | 24.10 |
| Daily low | 22.70 |
| Daily Volume | 38K |
| All-time high | 111.00 |
| 1y analyst estimate | 31.50 |
| Beta | 0.35 |
| EPS (TTM) | 0.15 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 6 May 2026 |
Downside potential
Loading...
Downside potential data
| AZT.OL | S&P500 | |
| Current price drop from All-time high | -80.18% | -1.82% |
| Highest price drop | -93.51% | -56.47% |
| Date of highest drop | 21 Dec 2009 | 9 Mar 2009 |
| Avg drop from high | -66.51% | -10.84% |
| Avg time to new high | 113 days | 12 days |
| Max time to new high | 3360 days | 1805 days |
COMPANY DETAILS
Marketcap
1.23B
Marketcap category
Small-cap
Description
ArcticZymes Technologies ASA, a life sciences company, develops, manufactures, and commercializes recombinant enzymes for use in molecular research, in vitro diagnostics, and biomanufacturing. The company offers shrimp alkaline phosphatase for cleanup prior to Sanger sequencing and next generation sequencing processes; cod UNG for use in viral and other molecular diagnostic assays for the removal of contaminating dU-DNA; salt active nucleases for the removal of nucleic acids during manufacturing of viral vectors, recombinant proteins, and other reagents; and double-strand specific DNases and derived kits for the removal of double stranded DNA. It also provides DNA/RNA polymerases for technology development for life science, molecular diagnostics, NGS, and synthetic biology; proteinase for microbiological diagnostics and liquid biopsies; and ligases for joining nucleic acids. The company serves the molecular tools, such as research and diagnostics, and biomanufacturing markets. It operates in Norway, Germany, Lithuania, France, Italy, the United Kingdom, rest of Europe, the United States, and internationally. The company was formerly known as Biotec Pharmacon ASA and changed its name to ArcticZymes Technologies ASA in June 2020. ArcticZymes Technologies ASA was founded in 1990 and is headquartered in Tromsø, Norway.
Employees
53
Website
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
Amid renewed trade and geopolitical uncertainty, the European stock market has seen declines, with the pan-European STOXX Europe 600 Index ending 0.98% lower. Despite these challenges, business activi...
January 27, 2026
As the European market navigates a landscape of mixed economic signals and resilient earnings results, the pan-European STOXX Europe 600 Index has shown modest gains, reflecting cautious optimism amon...
January 19, 2026
Amidst a mixed performance in major European stock indexes, with the STOXX Europe 600 Index ending slightly higher due to resilient economic data and earnings results, investors are keenly observing o...
January 19, 2026
As the European markets experience a wave of optimism with major indexes like the STOXX Europe 600 Index climbing 2.27%, investors are keenly observing opportunities that may be trading below their fa...
January 13, 2026
Amid optimism about the European economy and favorable interest rate conditions, major stock indexes across the region have experienced gains, with Germany's DAX and France's CAC 40 Index showing nota...
January 13, 2026
As the pan-European STOXX Europe 600 Index reaches new highs, buoyed by an improving economic environment and closing 2025 with its strongest yearly performance since 2021, investors are increasingly ...
January 9, 2026
As the European markets continue to flourish, with the STOXX Europe 600 Index reaching new highs and closing out 2025 with its strongest annual performance since 2021, investors are keenly eyeing stoc...
January 9, 2026
As the European markets continue to show strength, with the STOXX Europe 600 Index reaching new highs and closing 2025 with its best performance in years, investors are keenly observing opportunities ...
January 7, 2026
Amidst a buoyant economic environment, the European markets have experienced notable gains, with the STOXX Europe 600 Index reaching new highs and major indices like Germany's DAX and France's CAC 40 ...
January 7, 2026
ArcticZymes Technologies ASA (LTS:0DRV) reports a 24% revenue increase and strategic initiatives for future expansion despite challenges in key markets.
November 6, 2025
Next page